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ABStRAct
Stallions are natural reservoirs of equine arteritis virus (EAV) in their semen, representing a potential source of 
outbreaks. The carrier-state is testosterone-dependent, and clears spontaneously in 4 to 40% stallions. Reduction 
of testosterone secretion may be obtained with the anti-GnRH vaccine Equity. In this report, 16 naturally infected 
stallions excreting EAV in their semen were vaccinated twice with the vaccine EquityTM and monitored irregularly 
under field conditions for EAV viral load in their semen and plasmatic testosterone concentration. The results are 
indicated in months (M) after the first vaccine injection. Testosterone concentrations decreased from 1.7 to 0.2 ng/mL 
(P<0.002) after 3M. The EAV viral load decreased from 3.2×109 to 1.1×106 RNA copy/mL of semen (P<0.001) after 
5M. One stallion died at 7M for other reason. At M3-10, 12/15 stallions ceased to shed the virus in their semen. At M5-
10, 9/15 stallions had plasmatic testosterone concentrations of ≥ 0.5 ng/mL but the 6 others showed a persistently low 
testosterone concentration (≤0.3 ng/mL). Of the 14 stallions that were expected to recover their reproductive activity 
at the time of the next breeding season (<M12), 8 were EAV negative and produced foals, and 6 were not usable (4 
for reproductive deficiency and 2 for EAV positivity). All the stallions were EAV negative at M22, with one stallion 
being vaccinated a third time at M15. These results suggest that the anti-GnRH vaccination could help to clear EAV 
shedding in stallions, without a significant effect on reproductive capacity for most of them, but some present a long 
lasting reduced testosterone secretion. 
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introduction
Stallions are natural reservoirs of equine arteritis 
virus (EAV), which is the prototype virus of the 
Arteriviridae family (genus Arterivirus; order 
Nidovirales) (SNIJDER and MEULENBERG, 
1998). Equine arteritis virus is the causative 
agent of equine viral arteritis (EVA), which 
represents a reproductive and respiratory disease 
in horses and other equid species (DOLL et al., 
1957; MCCOLLUM and SWERCZEK, 1978; 
BALASURIYA et al., 2018). Exposure to equine 
arteritis virus (EAV) usually results in a mild 
or subclinical infection in immunocompetent 
horses. Clinical signs of EAV infection may vary 
in range and severity. Equine arteritis virus is 
frequently characterized by influenza-like signs 
in adult horses, but it may also cause abortion in 
mares, neonatal death, or interstitial pneumonia in 
young foals (TIMONEY and MCCOLLUM, 1993; 
MCCOLLUM et al., 1999). A variable percentage of 
stallions infected by EAV (ranging from 10% - 70%) 
will subsequently become asymptomatic carriers 
and thus ensure viral persistence in various horse 
populations worldwide. Stallions with a persistent 
infection can be divided into three categories on 
the basis of the duration of virus excretion in their 
semen: short-term (from 1 to 5 weeks following 
clinical recovery), intermediate-term (3 to 7 
months), and long-term carrier stallions (8 months 
to several years, or even all life) (TIMONEY et al., 
1987; TIMONEY and MCCOLLUM, 1993). Their 
role is central in the epidemiology of EAV infection, 
and stallions can potentially transmit the virus to 
susceptible mares by artificial insemination or 
natural mating. These stallions may also represent 
a further source of new outbreaks due to the 
emergence of new pathogenic strains (TIMONEY, 
1986; TIMONEY et al., 1986; MISZCZAK et 
al., 2012; MISZCZAK et al., 2015). Nonetheless, 
the spontaneous clearance of the virus in 4 to 
40% of stallions may occur after several months 
or years (TIMONEY and MCCOLLUM, 2000). 
The virus persists in the reproductive tract, 
mainly in the ampulla of the vas deferens, but 
also in the accessory sex glands (NEU et al., 
1987). The mechanism of EAV persistence in 
stallions has still not been fully defined, but the 
establishment and maintenance of the carrier state 
are testosterone-dependent (LITTLE et al., 1991; 
HOLYOAK et al., 1993b; MCCOLLUM et al., 
1994). In vitro studies suggest that horses could be 
divided into susceptible and resistant phenotypes, 
according to the susceptibility of their CD3(+) 
T lymphocytes to infection by EAV (GO et al., 
2012). This susceptibility has a genetic basis that 
has been demonstrated in four breeds (GO et al., 
2011). EAV interacts with some cellular elements 
in order to evade the equine immune response, and 
to establish persistent infection in the cells of the 
stallion’s reproductive tract (BALASURIYA et 
al., 2018; CAROSSINO et al., 2018). After acute 
experimental EVA infection, stallions may undergo 
a period of temporary subfertility that can persist 
for up to 16 weeks before returning to pre-exposure 
fertility levels (NEU et al., 1987; TIMONEY and 
MCCOLLUM, 1993). 
Various methods have been applied to eradicate 
EAV from infected semen, or to develop therapeutic 
treatment of EVA in stallions with persistent 
infections. Some of these methods have attempted 
to eliminate EAV from infected equine semen by 
using density gradient or single layer centrifugation, 
although the efficacy of these procedures has been 
variable (GOLNIK et al., 2004; MORRELL and 
GERAGHTY, 2006; MORRELL et al., 2013). 
Others have proposed the temporary chemical 
castration of infected stallions with an antagonist of 
the gonadotrophin-releasing hormone (GnRH), or 
an anti-GnRH vaccine. After treatment with a GnRH 
antagonist for 35 days, FORTIER et al. (2002) failed 
to induce total virus clearance in EAV shedder 
stallions, although testosterone concentrations and 
virus shedding both decreased transiently during the 
treatment. In a case study, BURGER et al. (2004) 
vaccinated one EAV shedder stallion with an anti-
GnRH vaccine (ImprovacTM, Zoetis, Australia). The 
stallion stopped shedding the virus in his semen 6 
months after the first injection. Using a very similar 
anti-GnRH vaccine (EquityTM, Zoetis, Australia), 
which was initially developed for controlling 
oestrus in mares (ELHAY et al., 2007), BURGER 
et al. (2006) vaccinated three EAV shedder stallions 
with EquityTM and one with ImprovacTM. EAV could 
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no longer be isolated from the semen of all these 
stallions after a few months. 
Here, we report in more detail the cases of 
these 3 stallions vaccinated with the anti-GnRH 
vaccine EquityTM and 13 other naturally infected 
EAV stallions shedding virus in their semen and 
vaccinated with the same vaccine. We monitored 
under field conditions: (a) the viral load in their 
semen and (b) the evolution of their reproductive 
capacity (testosterone secretion and fertility). 
Materials and methods
Stallions. Sixteen adult stallions from 16 different 
locations were included in this field study (Table 
1). They belonged to various breeds and their ages 
ranged between 5 and 24 years (11/16 stallions were 
14-20 years old). All had been naturally infected 
with EAV and subsequently became virus shedders 
in their semen. Seven stallions (J-P) had been 
infected during or subsequent to the 2007 French 
EAV outbreak. Sporadic infection was responsible in 
the remaining cases. After two consecutive positive 
viral diagnoses in semen by routine tests (RT-PCR 
and virus isolation), all the stallions were confirmed 
to be EAV positive, shedding virus in their semen. 
At the time of investigation, the stallions had shown 
virus shedding in their semen for different durations: 
short-term (n = 1), intermediate-term (n = 8) and 
long-term (n = 7), according to TIMONEY et al. 
(1987) and TIMONEY and McCOLLUM (1993). 
Anti-GnRH vaccination. All stallions were 
vaccinated intramuscularly twice with 200 µg 
of a GnRH peptide-protein conjugate (EquityTM) 
(ELHAY et al., 2007) 4 to 6 weeks apart. One 
stallion (I) received a third injection, 15 months 
after the first one, because EAV was still detected 
in his semen and his plasmatic testosterone level 
was increasing. This protocol was used safely by 
JANETT et al. (2009). A short clinical examination 
(rectal temperature, development of cutaneous 
reactions) was performed by veterinary practitioners 
following each vaccination. 
Sampling protocol. A periodic sampling 
protocol (semen for viral load and blood for 
plasma testosterone concentration) was proposed 
systematically to the stud managers before and after 
vaccination. It was planned that samples would 
continue to be sent to the laboratories until both 
EAV clearance and restoration of normal plasma 
testosterone concentration were obtained.
Determination of plasma testosterone level. 
Plasma samples were sent to the INRA laboratory 
of Nouzilly (France) and kept frozen (-20 °C). 
Plasma testosterone levels were determined using 
a direct radio-immunoassay method adapted from 
DEREVIERS et al. (1990) and ROTA et al. (2018). 
The intra- and inter-assay coefficients of variation 
were 5.7% and 5.9%, respectively, for quality 
control plasma samples containing 0.5 ng/mL 
testosterone.
Table 1. Characteristics of the 16 stallions shedding equine arteritis virus (EAV) in their semen and vaccinated with 


















A Standardbred Switzer-land 16 Jul 2004 1 short Aug 2004
B Thoroughbred France 17 Nov 2001 32 long Jul 2004
C Thoroughbred France 16 Apr 2000 49 long Jul 2004
D Arabian France 16 Feb 2006 3 intermediate May 2006
E Anglo-Arab France 15 Feb 2006 3 intermediate May 2006
F Holstein France 17 Jan 2006 6 intermediate Jul 2006
G Thoroughbred France 12 May 2005 19 long Dec 2006
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Healthy stallions produce fertile spermatozoa 
throughout the year, despite the yearly endogenous 
rhythm of reproductive hormones. Plasma 
testosterone in the stallion is higher during the 
breeding season (from April to July) compared to 
the non-breeding season (August to March) with 
concentrations ranging from 0.3, to more than 
1.7 ng/mL throughout the year (RAESIDE, 1979; 
THOMPSON et al., 1985; ROSER and HUGHES, 
1992; SIEME et al., 2001). Therefore, we defined 
a threshold of 0.3 ng/mL to decide if stallions 
presented low testosterone levels.
Viral detection and quantification. Chilled 
semen samples were sent immediately to the Labeo 
Frank Duncombe laboratory (France), where an 
aliquot was taken and kept frozen (-80 °C). Viral 
load was then estimated following retrospective 
analysis by qRT-PCR. 
RNA purification: Equine semen was 
microcentrifuged at 13,800 g for 2 min and 140 
µL of the supernatant was used for nucleic acid 
purification. Viral RNA was extracted using the 
QIAamp® Viral RNA isolation kit (Qiagen, Hilden, 
Germany), and eluted in a final volume of 60 µL 
according to the manufacturer’s instructions.
Generation  of in vitro transcribed RNA. An in 
vitro transcribed (IVT) EAV RNA containing 
complete ORF7 was used for EAV quantification. 
The IVT RNA was generated using the 
MEGAshortscriptTM Kit (Ambion Inc., Austin, TX, 
USA) according to the manufacturer’s instructions, 
and adapted from a previous study (LU et al., 2008). 
The IVT RNA transcripts were stored at -80 °C 
until use. The RNA transcripts were quantified by 
spectrophotometric analysis using the NanoDrop 
2000c (Thermo Fischer Scientific) and concentration 
of copy per microliter was calculated. The IVT RNA 
stock solution was quantified at 6.0×103 ng/µL and 
the IVT copy number was evaluated at 8.5 ×1013 
copy per 5 µL (nucleic acid reaction volume in RT-
PCR) according to a previously described method 
(MISZCZAK et al., 2011). The dilution of IVT 
RNA (1010 to 1 copy) was carried out in RNase- and 


















H Anglo-Arab France 14 Feb 2006 12 long Feb 2007
I Anglo-Arab France 24 Oct 2006 4 intermediate Feb 2007
J French saddle horse France 18 Nov 2007 6 intermediate May 2008
K New Forest France 16 Aug 2007 9 long May 2008
L Anglo-Arab France 16 Feb 2008 3 intermediate May 2008
M Foreign (Polish) France 10 Aug 2007 9 long May 2008
N Lusitanian France 17 Aug 2007 9 long May 2008
O French Standardbred France 7 Mar 2008 4 intermediate Jul 2008
P French saddle Pony France 5 Jan 2008 6 intermediate Jul 2008
* Status of the stallion for EAV shedding, based on the duration of virus excretion in semen before vaccination: short-term (from 
1 to 5 weeks after clinical recovery), intermediate-term (3 to 7 months) and long-term carrier stallion (from 8 months to years) 
according to Timoney et al. (1987) and Timoney and McCollum (1993).
Table 1. Characteristics of the 16 stallions shedding equine arteritis virus (EAV) in their semen and vaccinated with 
the anti-GnRH vaccine EquityTM (continued) 
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EAV real-time RT-PCR detection and 
quantification. A previously described one-tube real-
time TaqMan RT-PCR assay, targeting the ORF7 
of the EAV genome encoding the nucleocapsid, 
was used for EAV detection and quantification 
(BALASURIYA et al., 2002). Quantitative RT-PCR 
was performed using the One Step PrimeScriptTM 
RT-PCR Kit (Perfect Real Time) (TaKaRa, Otsu, 
Japan) in a SmartCycler® II System (Cepheid, 
Sunnyvale, CA, USA). Briefly, each reaction was 
set up in 25 µL, according to the manufacturer’s 
instructions, which contained 12.5 µL of 2X One 
Step RT-PCR buffer III, 0.5 µL of both TaKaRa Ex 
TaqTM HS (5 U/ µL) and PrimeScriptTM RT enzyme 
Mix II, 600 nM of forward and reverse primers 
(0.75 µL of each), 200 nM of probe (0.5 µL), 4.75 
µL of nuclease-free water and 5 µL of test sample 
RNA. The following thermocycling conditions 
were used for each reaction: 5 min at 42 °C, 10 s at 
95 °C, followed by 45 cycles at 95 °C for 5 s and 60 
°C for 1 min. The analytical quantification of EAV 
in semen samples was performed in EAV nucleic 
acid by real-time PCR assay, with serial decimal 
dilutions of IVT RNA (1010-101 copy). Linearity 
of the regression analysis and PCR efficiency in 
the assay gave an R2 = 0.997 and linear equation 
y = -3.653x + 47.689, respectively. Quantification 
of EAV viral load in each semen sample was 
determined by comparison with quantified serial 
decimal dilutions of IVT RNA. For each assay, 
the nucleic acid extracted from the semen samples 
and serial dilutions of IVT RNA were processed in 
duplicate.
Evaluation of fertility. Fertility was assessed for 
all French stallions according to the foaling rate 
determined by SIRE (French data base for horse 
registration, I.F.C.E., Pompadour, France), and 
defined as the number of mares declared as having 
delivered a foal, divided by the total number of 
mares bred by this stallion, either by hand mating 
or by artificial insemination with fresh semen, used 
immediately after collection during the breeding 
season under consideration. Mares inseminated with 
frozen semen were excluded from this calculation. 
Irregular data. The sampling protocol (blood 
collection for determination of testosterone 
concentration, semen collection for viral load 
analysis) was adapted by the stud managers, 
and the stallions were not always sampled at the 
expected time-points (Fig. 1 and Tables 2 and 3). 
Prior to the first immunization, plasma testosterone 
concentration was measured at least once (except 
for stallions A and G). Stallion A, a male not used in 
reproduction, was only monitored for viral excretion, 
but not regarding testosterone secretion. Stallion 
G was not analysed for plasmatic testosterone 
concentration before and just after vaccination, but 
was sampled at month 11 when, EAV negative, he 
was unable to breed mares successfully. Stallion 
C died 7 months post-vaccination due to cardiac 
problems that were not related to the immunization 
protocol. Stallion P was only monitored for EAV by 
regular RT-PCR without viral load quantification 
before the first injection and no testosterone 
sampling was performed between the first and 7 
months. 
Policy and ethics. This study complied 
with French and Swiss laws relating to animal 
experimentation. The horses evaluated in this 
experiment were not research animals, and were 
managed with a high level of care. Their husbandry 
and care were carried out under their owners’ 
responsibility. The owners were informed, and 
consented to participate in this study.
Statistical analyses. Non-parametric statistics 
were used due to the small number of subjects 
and the nature of the measurements. Data were 
analysed with XLSTAT software (Addinsoft, Paris, 
France). Data on virus content and testosterone 
levels were presented by medians and shown in 
box-plot form, in accordance with Tukey’s model 
(TUKEY, 1977). The results concerning virus 
content and testosterone levels were not considered 
as matched data due to missing samples for some 
time points. The values for each time point were 
compared using the Kruskal-Wallis test. When 
the Kruskal-Wallis test was significant, post hoc 
(multiple comparisons) tests were performed with 
the Steel-Dwass-Critchlow-Fligner procedure. The 
comparisons were made across time-points, and 
mainly with respect to pre-vaccination values.
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Table 2. Plasmatic testosterone concentrations in stallions shedding EAV in their semen before and after anti-GnRH 
vaccination with EquityTM. (EAV: Equine arteritis virus)
Stallion




Months after vaccination (1st injection)


















B 2.0 0.1 0.1 0.1 0.2 1.2 0.6 2.2 0.5
C2 0.6 0.1 0.0 1.1 / Dead Dead Dead Dead
D 1.5 0.2 0.2 0.3 0.3 0.8 / / /
E 1.7 0.2 0.2 0.2 0.6 1.2 / / /
F 1.5 0.5 0.2 0.2 0.3 0.2 0.2 0.2 0.3
G / / / / / / 0.1 0.3 /
H 0.7 0.2 0.3 0.2 0.2 0.3 / 0.1 /
I3 0.7 0.2 0.3 0.3 0.4 0.5 1.4 / 1.0
J 2.1 0.9 / 0.2 1.1 / / / 1.1
K 1.7 0.4 / 0.5 0.8 / / / 0.6
L 1.7 0.4 / 0.2 0.3 0.5 0.5 0.2 /
M 1.7 1.2 / 0.2 0.2 0.2 0.1 0.1 0.1
N 2.1 1.8 / 0.1 0.1 0.2 0.1 0.0 0.1
O 2.4 0.4 0.2 0.3 0.3 / / / /
P 1.6 / / / 1.0 1.3 1.8 / /
“/”: no sampling; Plasmatic testosterone concentration values lower or equal to 0.3 ng/mL are highlighted in grey; 1 Stallion A 
was not a reproductive stallion; 2 Stallion C died at month 7 for reasons not related to the vaccination protocol; 3 Stallion I was 
vaccinated a third time at month 15 period.
Fig. 1. Chronology and frequency of analyses performed in 16 stallions shedding EAV in their semen before and after vaccination 
with the anti-GnRH vaccine EquityTM (EAV: Equine arteritis virus) (in months after the first injection).  EAV detection and 
viral load quantification in semen sample.  Testosterone analysis in serum sample.  Vaccination with the Equity® vaccine. 
 Death of stallion C. Stallion I received a third injection because EAV was still detected in his semen at month 15 and because 
testosterone was increasing. At the first injection, stallion P was only monitored by regular RT-PCR as an EAV shedder without 
viral load quantification.
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Results
All results, tables and figures are presented 
with respect to the number of months after the 1st 
injection of vaccine. 
Vaccine tolerance. After immunization, only 
a transient rise in body temperature or a small 
transient painful swelling at the injection site was 
detected in some stallions. All adverse effects 
resolved within 2-3 days post-vaccination. 
Plasma testosterone level. Plasma concentrations 
of testosterone ranged from 0.6 to 2.4 ng/mL 
(median: 1.7 ng/mL) before the first injection 
(Table 2 and Fig. 2A). When compared to the 
pre-vaccination value, testosterone concentration 
after injections decreased during months 1-2 (0.4 
to 1.7 ng/mL) (P<0.005) and remained generally 
low until months 5-6 (0.2 ng/mL) (P<0.001). 
Thereafter, testosterone concentrations tended to 
increase during months 7 to 10, but still remained 
below pre-vaccination levels 11 to 12 months post-
vaccination (Fig. 2A). During the first 6 months 
after the first injection, 11 out of 13 stallions 
showed, at least once, a plasma testosterone 
concentration lower or equal to 0.3 ng/mL. After 
5-6 months, two groups of stallions were observed. 
One group of 9 stallions (B-D, E, I-L and P) showed 
increased testosterone levels (≥ 0.5 ng/mL), the 
other group of 6 stallions (F-H and M-O) still had 
low testosterone concentrations (≤0.3 ng/mL). 
EAV detection and quantification in semen. 
Before vaccination, or at the time of the first 
injection, the EAV viral load ranged from 9.4×107 to 
2.2×1010 RNA copy/mL of semen (median: 3.2×109 
RNA copy/mL of semen) (Table 3 and Fig. 2B). 
Thereafter, the EAV viral load decreased at months 
3-4 (P<0.0001) and remained low (for instance 
at months 5-6: median 1.1×106 RNA copy/mL of 
semen, P<0.0001) compared to pre-vaccination 
values. The median values were 0 (undetectable) 
from months 7-8 to months 9-12 (end of Fig. 2B) 
and until months 21-22.
Fig. 2. Evolution of plasma testosterone concentrations (A) and EAV viral load in the semen (B) of 16 stallions 
shedding EAV in their semen before and over 12 months after vaccination with the anti-GnRH vaccine EquityTM 
(EAV: Equine arteritis virus) (in months after the first injection). ↓ - injection of anti-GnRH vaccine; Box and whisker 
plots represent the heterogeneity of the stallion population at each time period (every two months). Boxes represent the 
interquartile (IQ = Q3-Q1) ranges of plasma testosterone concentrations (A) and EAV viral load in semen (B). The bottom and 
top of the boxes represent the 1st (Q1) and 3rd (Q3) quartiles, respectively, and the horizontal lines inside the boxes represent the 
median values. Vertical lines emanating from each box are limited by the minimal value for lower whisker and by mathematical 
calculation of upper whisker plots (UW = Q3+1.5×IQ). Outliers (values>UW) are represented by black dots. n - number of 
stallions included at each time point. The letters (X, Y, Z) indicate significant differences between times (Fig. 2A - P≤0.01; Fig. 
2B - P≤0.03).
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At the end of the experiment, EAV clearance was 
observed in all stallions (except for stallion C, who 
died in month 7). Most of the stallions (12 out of 15) 
became EAV negative between months 3 and 10 (A, 
B, D-G and K-P). Stallions H and I presented EAV 
viral loads of 1.0×105 and 2.1×105 RNA copy/mL at 
months 13-14 and 15-16, respectively. Three stallions 
(H, I, J) became EAV negative after 18 months. 
Moreover, all stallions were confirmed as 
having EAV negative semen by qRT-PCR and virus 
isolation at least once during the breeding season 
following their first EAV negative result.
Fertility at the first breeding season post-
vaccination. Of the 16 stallions monitored at the 
start of the study, 14 had produced foals before 
(Table 4), and were expected to breed mares again 
during the season following the vaccination, so 
within 12 months. Of these 14 stallions, 2 were not 
used since they were still EAV positive at the start 
of the following breeding season (H and I). Of the 
12 remaining stallions, 4 stallions were not used 
since they were unable to breed mares (F, G, M, 
N). Finally, 8 stallions (B-E, J-L, O and P) were 
EAV negative and bred mares successfully during 
the next breeding season (Table 4). For these 8 
stallions, individual foaling rates ranged from 27 to 
88% before vaccination and from 29 to 72% after 
vaccination; 18 foals per stallion (from 3 to 54 
foals) were born from the mares bred during the last 
season before vaccination vs. 12 foals per stallion 
(ranging from 4 to 27 foals) during the season 
following the vaccination. 
Table 3. Quantification of viral load (EAV) in semen samples of 16 stallions before and after vaccination with the 
anti-GnRH vaccine EquityTM
Stallion




Months after vaccination (1st injection)
1-2 3-4 5-6 7-8 9-10 11-12 13-14 15-16 17-18 19-20 21-22
A1 2.2×1010 6.4 ×109 6.3×106 3.4×105 4.5×105 0 / / / / / 0
B 1.2×1010 1.2×1010 1.6×107 7.7×105 0 0 0 0 / 0 / /
C2 2.1×1010 5.5×104 3.8×106 1.1×106 2.4×105 dead dead dead dead dead dead dead
D 9.4×107 3.1×107 5.1×104 0 0 0 0 0 / 0 / /
E 8.5×109 5.2×109 5.7×106 2.7×107 0 0 0 0 / / / 0
F 9.9×109 / 5.7×106 2.0×106 5.1×105 0 / 0 / 0 / /
G 2.6×109 / / / 0 / / / / / / 0
H 5.8×109 1.7×108 1.7×107 2.4×106 1.7×106 7.3×105 3.6×105 1.0×105 / / 0 /
I 3 3.4×109 1.5×109 1.3×109 1.5×108 3.8×108 5.1×107 2.1×109 7.1×107 2.1×105 / / 0
J 8.3×108 / 2.1×107 1.6×106 1.7×105 / / / / / 0 /
K 1.5×109 / 0 0 0 0 / / / / / /
L 4.0×108 / 7.9×106 1.2×106 0 0 / / / / / /
M 6.6×108 / 1.1×107 0 0 / / / / / / /
N 2.5×109 / 0 0 0 / / / / / / /
O 3.2×109 1.9×105 / 0 / / / / / / 0 /
P4 + / / 0 0 0 / / / / /
* Number of RNA copy/mL of semen sample and detected by qRT-PCR. “/”: no sampling; “+”: EAV positive sample detected by 
regular RT-PCR without quantification; “0”: undetectable = negative results, all negative results are highlighted in grey; 1 - Stallion 
A was not a reproductive stallion; 2 - Stallion C died at month 7 for reasons not related to the vaccination protocol; 3 - Stallion I 
was vaccinated a third time at month 15; 4 - At first injection, Stallion P was only monitored by regular RT-PCR without viral load 
quantification. 
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Discussion
This report describes a cohort of naturally EAV 
infected stallions immunized with an anti-GnRH 
vaccine and monitored under field conditions. In 
most stallions, we observed a decrease followed by 
an increase in plasmatic testosterone levels. At the 
same time, in all stallions we observed a decrease of 
the EAV viral load in their semen until undetectable 
levels. Most stallions used in breeding produced 
foals during the following breeding season. These 
results were obtained from a cohort of stallions 
characterized by high heterogeneity with regard 
to location, breed, age and EAV status based on 
the previous duration of virus excretion in the 
semen. Therefore, this experimental group can be 
considered as being representative for the general 
population of domesticated stallions in Europe.
The significant and rapid decrease in testosterone 
levels observed in our study group during the 
first two months after anti-GnRH vaccination has 
already been reported by other authors with the 
vaccine EquityTM (JANETT et al., 2009), as well 
as with other anti-GnRH vaccines (MALMGREN 
et al., 2001; BURGER et al., 2004; STOUT and 
COLENBRANDER, 2004; CLEMENT et al., 
2005; TURKSTRA et al., 2005). This observation 
is in agreement with the suppression of the cyclic 
ovarian activity in mares observed during the first 
months following vaccination with both EquityTM 
and Improvac® vaccines (CARD et al., 2007; 
ELHAY et al., 2007; SCHULMAN et al., 2013).
Table 4. Fertility of stallions shedding EAV in their semen before and after vaccination with the anti-GnRH vaccine 




EAV positive First breeding season after vaccination 
Foaling rate1 
(%)






A Not breeding stallion 0 Not measured
Not breeding 
stallion
B 53 0 > = 0.3 ng/mL Yes 29
C 64 Dead Dead Dead
D 66 0 > = 0.3 ng/mL Yes 55
E 88 0 > = 0.3 ng/mL Yes 72
F 71 0 Too low 2 No
G 62 0 Too low 2 No
H 67 Positive Not measured No
I 57 Positive > = 0.3 ng/mL No
J 57 0 > = 0.3 ng/mL Yes 57
K 73 0 > = 0.3 ng/mL Yes 58
L 46 0 > = 0.3 ng/mL Yes 50
M 63 0 Too low 2 No
N 54 0 Too low 2 No
O 69 0  = 0.3 ng/mL Yes 68
P 27 0 > = 0.3 ng/mL Yes 56
1 - Foaling rate: number of mares declared as having delivered a foal, divided by the total number of mares bred by this stallion. 
Only mares bred by hand mating or inseminated with fresh semen used immediately were taking into account in that ratio; 2 - Too 
low: <0.3 ng/mL
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In the present field study, the mean duration of 
decreased plasma testosterone concentrations (≤0.3 
ng/mL) was 10 months (from months 1-2 to months 
11-12 post-vaccination) (Fig. 2A). This duration 
was variable among stallions and ranged from 4 to 
16 months or more, but is in broad agreement with 
the duration of 6 months of very low testosterone 
levels previously observed in 4/5 stallions after 
three injections of EquityTM (JANETT et al., 2009). 
Other vaccines used in stallions proved not to be 
so efficient and required more than two injections 
(MALMGREN et al., 2001; CLEMENT et al., 
2005). Therefore, the EquityTM vaccine can be 
considered as an efficient anti-GnRH vaccine for 
stallions which induces a significant decrease of 
testosterone plasma levels during 4 months and 
more.
The majority of the stallions’ semen was shown to 
be EAV-free within 3 to 10 months post-vaccination, 
and all stallions were EAV-free after 22 months. 
Before or at the first injection with EquityTM, the 
viral load ranged from 9.4×107 to 2.2×1010 copy/mL 
of semen, which is a rather homogeneous result. 
Thereafter, the viral load decreased to 5.1×104 - 
2.7×107 copy/mL (the general range being 105-106 
copy/mL) in the last semen sample before the first 
negative sample. In light of these findings, a viral 
load lower than 105-106 copy/mL of semen could be 
considered, in the majority of cases, as a predictive 
threshold value before total EAV clearance is 
reached.
It is not yet fully understood how spontaneous 
clearance of EAV happens in intact stallions. 
Monitoring EAV viral load and EAV clearance in 
semen was described previously by culture and/
or regular RT-PCR (BALASURIYA et al., 2018). 
By applying a quantitative approach, the present 
report gives new information about the evolution of 
EAV before clearance. This quantitative approach 
of viral output in carrier stallions could possibly 
be used to monitor natural clearance. However, in 
intact stallions, it takes place in an intact genital 
tract in the presence of testosterone, which was not 
the case here. 
Previous studies revealed that testosterone 
plays an essential role in the establishment and 
maintenance of the carrier-state in persistently EAV 
infected stallions. EAV was cleared from carrier 
stallions 4 to 26 days post-castration, but viral 
excretion was maintained if castrated stallions were 
testosterone supplemented (LITTLE et al., 1991). 
In addition, it was not possible to establish a carrier 
state in experimentally EAV infected geldings 
(MCCOLLUM et al., 1994). The nature and extent 
of pathological changes in the reproductive tracts 
of prepubertal and peripubertal colts associated 
with EAV infection demonstrate the relationship 
between the stage of reproductive tract maturity 
and susceptibility (HOLYOAK et al., 1993a). 
Using a GnRH antagonist in EVA carrier stallions 
for 5 weeks, FORTIER et al. (2002) observed 
temporary EAV clearance just after treatment in all 
stallions, even though 2/5 stallions subsequently 
regained their shedding state. The first case study 
described the clearance of the virus in a stallion 
six months after vaccination with the Improvac® 
vaccine, following a strong decrease in plasmatic 
testosterone concentration over five months 
(BURGER et al., 2004). Similarly, in our study, 
the decrease in plasma testosterone concentrations 
beginning 1-2 months after the first injection, 
and lasting 2 to 4 months or more, was followed 
by a significant decrease in viral load 3-4 months 
post-vaccination. It might be hypothesized that 
testosterone has to be reduced for 2 months or more 
to induce EAV clearance. 
In the present study, the semen of all vaccinated 
stallions (15 out of the 15 stallions monitored for 
22 months) became EAV negative after anti-GnRH 
vaccination: in 12 of them before 11 months and in 
3 between 19 and 22 months (including a stallion 
with a third vaccine injection at 15 months). It 
cannot be concluded that all these viral clearances 
were a consequence of anti-GnRH vaccination, as 
spontaneous clearance may also have occurred at 
any time. The lack of a control group of mostly 
active breeding stallions with placebo treatment 
represents a major limitation of this field study. 
Nonetheless, it has been reported that the percentage 
of spontaneous EAV clearance following natural 
infection in a population of more than 200 stallions 
varied from 4 to 42%, depending on the breed 
(TIMONEY and MCCOLLUM, 2000). If one 
considers this 42% as the maximum reference value 
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for spontaneous EAV clearance, then the value of 
100% (15 out of 15 stallions) observed in the present 
study is encouraging. Nonetheless, our results need 
to be confirmed in a controlled designed study.
In France, from 2005 to 2009, the foaling rate 
of Warmblood stallions was shown to be 62% after 
natural service and 68% after artificial insemination 
with fresh semen used immediately after collection 
(data on 3000 stallions per year). Before GnRH 
vaccination, all breeding stallions in our field study 
produced foals with a low to normal foaling rate, and 
presented normal testosterone levels. One year after 
anti-GnRH vaccination, two different populations 
of stallions could be identified according to their 
testosterone level: the first group showing plasma 
testosterone concentrations higher than 0.3 ng/
mL and able to breed and fertilize mares, and the 
second group of stallions presenting low plasma 
testosterone concentrations (≤0.3 ng/mL). In the 
first group, stallion B, with the lowest foaling rate 
after the first breeding season post-vaccination 
(29%, n = 28 mares), reached a foaling rate of 68% 
in the next breeding season (n = 44 mares). Stallions 
from the first group seemed to regain the status of 
normal fertile breeding stallions after vaccination. 
However, regarding the second group of stallions, 
the risk of long-lasting reduced testosterone 
secretion after GnRH vaccination was confirmed. 
Indeed, one to two years after vaccination with 
the EquityTM or ImprovacTM vaccines, the rate 
of non-recovery of reproductive function has 
been estimated to be 8 to 40% in stallions and 
in mares (IMBODEN et al., 2006; CARD et al., 
2007; ELHAY et al., 2007; JANETT et al., 2009; 
SCHULMAN et al., 2013). Some stallions in the 
second group may also have been affected by 
a spontaneous alteration of their reproductive 
capacity, i.e. by idiopathic subfertility/infertility 
observed in aged stallions. Scientists assume that 
at the beginning of this condition, there is an initial 
decline in important testicular factors necessary for 
interactions between Sertoli and germ cells. Leydig 
cell dysfunction, along with reduced testosterone 
secretion are observed only when the condition is 
severe (ROSER, 1997). On the other hand, if no 
stallions in the second group represented such a 
case, the risk of long-lasting immunocastration due 
to anti-GnRH vaccination could be estimated in our 
study cohort as being 31% (4 out of 13 stallions 
with data before or at 12 months). As such, this risk 
represents a major concern for the use of anti-GnRH 
vaccination in valuable breeding stallions, but was 
accepted by the owners of EAV shedding stallions 
in our study compared to surgical castration or 
culling. To counteract this untoward effect, an 
agonist of GnRH, buserelin, was administered daily 
from 2 months before the beginning until the end 
of the breeding season in those 4 stallions. Three 
stallions subsequently presented daily increasing 
plasmatic testosterone concentrations and 
produced foals (VIDAMENT et al., 2010). This 
fact gives us an indication in favour of the long-
lasting immunocastration hypothesis, since GnRH 
supplementation was seldom efficient in idiopathic 
subfertile/infertile stallions (STOUT, 2005).
During follow-up, the characteristics of the 
semen and testes of the majority of the stallions 
were documented before and over 6-12 months 
after vaccination: evaluation of the number of 
spermatozoa per ejaculate, their motility and 
morphology, and measurement of testicular size by 
echography. Since these analyses were performed in 
field laboratories, the results have not been reported 
here. However, the stallions often presented a 
strong decrease in the number of spermatozoa, 
an increase in the number of detached heads, a 
reduction in testicular size, and a decreased libido. 
This was observed in both populations (see above) 
4-6 months after vaccination. In the population 
of stallions with an increase in testosterone 
concentrations above 0.3 ng/mL, production of 
spermatozoa and testicular size rose two months 
after this increase. The schedule of events was in 
agreement with those observed by JANETT et al., 
(2009) following vaccination with the EquityTM 
vaccine. Indeed, such modifications of testicular 
function are usually observed after any temporary 
insult to spermatogenesis (JOHNSON et al., 1997).
Finally, our results obtained without control 
stallions and with irregular field data should be 
interpreted with caution and need to be confirmed 
in a controlled designed study to evaluate viral 
clearance rate, as well as the risk of long lasting 
immunocastration after this type of immunization.
F. Miszczak et al.: Anti-GnRH vaccination in EAV infected stallions
Vet. arhiv 90 (6), 543-556, 2020554
CARD, C., T. RAZ, R. LEHEIGET, G. SIBERT (2007): 
GnRF Immunization in Mares: ovarian function, return 
to cycling, and fertility. In: The Annual Convention of the 
AAEP, Orlando, FL, pp. 576-577.
CAROSSINO, M., P. DINI, T. S. KALBFLEISCH, A. T. 
LOYNACHAN, I. F. CANISSO, K. M. SHUCK, P. J. 
TIMONEY, R. F. COOK, U. B. R. BALASURIYA (2018): 
Downregulation of MicroRNA eca-mir-128 in seminal 
exosomes and enhanced expression of CXCL16 in the 
stallion reproductive tract are associated with long-term 
persistence of equine arteritis virus. J. Virol. 92. 
 DOI: 10.1128/JVI.00015-18
CLEMENT, F., M. VIDAMENT, P. DAELS, F. VAN 
DER MEER, J. L. LARRY, B. COLENBRANDER, J. 
TURKSTRA (2005): Immunocastration in stallions: effect 
on spermatogenesis and behaviour. Anim. Reprod. Sci. 89, 
230-233. 
DEREVIERS, M. T. H., M. COPIN, M. SECK, C. 
MONETKUNTZ, C. CORNU, I. FONTAINE, C. 
PERREAU, J. M. ELSEN (1990): Stimulation of 
testosterone production by PMSG injection in the ovine 
male - effect of breed and age and application to males 
carrying or not carrying the F booroola gene. Anim. 
Reprod. Sci. 23, 21-32. 
 DOI: 10.1016/0378-4320(90)90012-5
DOLL, E. R., R. E. KNAPPENBERGER, J. T. BRYANS 
(1957): An outbreak of abortion caused by the equine 
arteritis virus. Cornell Vet. 47, 69-75. 
ELHAY, M., A. NEWBOLD, A. BRITTON, P. TURLEY, 
K. DOWSETT, J. WALKER (2007): Suppression of 
behavioural and physiological oestrus in the mare by 
vaccination against GnRH. Aust. Vet. J. 85, 39-45. 
 DOI: 10.1111/j.1751-0813.2006.00092.x
FORTIER, G., M. VIDAMENT, F. DECRAENE, B. FERRY, 
P. F. DAELS (2002): The effect of GnRH antagonist on 
testosterone secretion, spermatogenesis and viral excretion in 
EVA-virus excreting stallions. Theriogenology 58, 425-427. 
 DOI: 10.1016/s0093-691x(02)00848-8
GO, Y. Y., E. BAILEY, D. G. COOK, S. J. COLEMAN, 
J. N. MACLEOD, K. C. CHEN, P. J. TIMONEY, U. B. 
BALASURIYA (2011): Genome-wide association study 
among four horse breeds identifies a common haplotype 
associated with in vitro CD3+ T cell susceptibility/
resistance to equine arteritis virus infection. J Virol. 85, 
13174-13184. 
 DOI: 10.1128/JVI.06068-11
GO, Y. Y., E. BAILEY, P. J. TIMONEY, K. M. SHUCK, U. 
B. R. BALASURIYA (2012): Evidence that in vitro 
susceptibility of CD3(+) T lymphocytes to equine arteritis 
virus infection reflects genetic predisposition of naturally 
infected stallions to become carriers of the virus. J. Virol. 
86, 12407-12410. 
 DOI: 10.1128/JVI.01698-12
GOLNIK, W., B. SORDYL, W. NIZANSKI, M. KLIMOWICZ 
(2004): Application of EquiPure to improve stallion sperm 
quality and its equine arteritis virus decontamination. 
Medycyna Wet. 60, 508-511. 
HOLYOAK, G. R., R. C. GILES, W. H. MCCOLLUM, T. V. 
LITTLE, P. J. TIMONEY (1993a): Pathological changes 
conclusion 
In most stallions that were naturally EAV 
infected and then immunized with an anti-GnRH 
vaccine, a decrease was observed in plasmatic 
testosterone levels at month 1-6, lasting 4 months 
or more, as well as a decrease in viral load in the 
semen until undetectable levels at months 3-10. At 
months 9-10, most stallions showed an increasing 
plasmatic testosterone concentration again, but 
others still had very low levels until months 13-14. 
Most stallions produced foals during the following 
breeding season (8/14), but the others were not 
usable (4 for reproductive deficiency and 2 for EAV 
positivity). All stallions finally had EAV negative 
semen at month 22. These results need to be 
confirmed in a controlled designed study. 
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SAŽETAK
Pastusi su prirodni rezervoar uzročnika virusnog arteritisa konja (EAV), koji se izlučuje u sjemenu, te su zbog toga 
i potencijalni izvor pojave bolesti. Status prenositelja je ovisan o testosteronu i spontano nestaje u 4 do 40 % pastuha. 
Izlučivanje testosterona moglo bi se smanjiti anti-GnRH cijepljenjem. U ovom je istraživanju 16 prirodno inficiranih 
pastuha, koji su izlučivali EAV u sjemenu, cijepljeno dva puta cjepivom EquityTM te je u nepravilnim razmacima i u 
terenskim uvjetima praćena količina virusa u sjemenu i koncentracija testosterona u plazmi. Rezultati su prikazani 
prema mjesecima (M) poslije prvog cijepljenja. Koncentracija testosterona smanjena je s 1,7 na 0,2 ng/mL (P < 0,002) 
poslije tri mjeseca. Poslije pet mjeseci količina virusa smanjena je s 3,2 × 109 na 1,1 × 106 RNA kopija/mL sjemena 
(P < 0,001). Jedan je pastuh uginuo 7 mjeseci nakon prvog cijepljenja. Od trećeg do desetog mjeseca, 12 od 15 pastuha 
prestalo je izlučivati virus u sjemenu. Od petog do desetog mjeseca, 9 od 15 pastuha imalo je koncentraciju testosterona 
u plazmi ≥ 0,5 ng/mL, a njih šestero pokazalo je trajno nisku koncentraciju testosterona (≤ 0,3 ng/mL). Od 14 pastuha, 
od kojih se očekivao oporavak reproduktivne aktivnosti u sljedećoj sezoni rasploda (< M 12), 8 je bilo negativno na 
EAV i dalo ždrijebe, a 6 nije bilo za rasplod (4 zbog reproduktivne deficijencije i 2 jer su bili pozitivni na EAV). Svi 
su pastusi bili negativni na EAV poslije 22 mjeseca, s tim da je jedan pastuh nakon 15 mjesci treći put cijepljen. Ovi 
rezultati pokazuju da bi anti-GnRH cijepljenje moglo pomoći u eradikaciji EAV-a u pastuha, bez osobita utjecaja na 
reproduktivnu sposobnost većine njih, osim što je u nekih smanjeno izlučivanje testosterone dulje potrajalo. 
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